Camrelizumab|1798286-48-2|(卡瑞利珠单抗; SHR-1210)-陌孚医药/Medlife

您当前的位置：

Camrelizumab (Synonyms: 卡瑞利珠单抗; SHR-1210)

目录号: PL08960

CAS No. :1798286-48-2

商品编号	规格	价格	会员价
PL08960-1mg	1mg	¥3214.00	请登录
PL08960-5mg	5mg	¥11250.00	请登录
PL08960-10mg	10mg	询价	询价
PL08960-50mg	50mg	询价	询价

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Camrelizumab
中文别名	卡瑞利珠单抗
英文名称	Camrelizumab
英文别名	Camrelizumab
Cas No.	1798286-48-2
包装储存	Please store the product under the recommended conditions in the Certificate of Analysis.

产品详情

Camrelizumab (SHR-1210) 是一种人源化的 IgG4-κ 抗 PD-1 单克隆抗体 (mAb)。Camrelizumab 以 3 nM 的高亲和力与 PD-1 结合，抑制 PD-1 和 PD-L1 的结合作用的 IC₅₀ 值为 0.70 nM。Camrelizumab 是一种有效的抗 PD-1/PD-L1 药物，可用于癌症研究，包括非小细胞肺癌、食管鳞状细胞癌、霍奇金淋巴瘤和晚期肝癌等。

生物活性

Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC 50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al.

IC50 & Target[1][2]

IC50: 0.70 nM ( PD-1/PD-L1 interaction)

体外研究(In Vitro)

In a T cell proliferation assay using tuberculin treated peripheral blood mononuclear cells, Camrelizumab induces a T cell proliferation at an EC50 of 0.11 nM. In a similar assay measuring IFN-gamma secretion, Camrelizumab induces IFN-gamma production at an EC50 of 0.38 nM.
has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Camrelizumab (3 mg/kg) combines with apatinib (200 and 100 mg/kg) inhibits the tumor inhibition rates reached 63.1% and 87.3%, respectively in human PD-1 transgenic mice.
has not independently confirmed the accuracy of these methods. They are for reference only.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

ClinicalTrial

参考文献

[1]. Kuimin Mei, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. J Immunother Cancer. 2021 Mar;9(3):e002191.
[2]. Jason D Lickliter, et al.A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug Des Devel Ther

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation